5-androstene-16-fluoro-17-one

Known as: 16alpha-Fluoroandrost-5-en-17-one, Dehydroepiandrosterone Analog 8354, FLUASTERONE 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Dehydroepiandrosterone (DHEA) is a potent inhibitor of prostate carcinogenesis in rats. However, concerns related to the possible… (More)
  • table I
  • table II
  • figure 1
Is this relevant?
2005
2005
We compared in vivo radioprotective efficacy of 5-androstenediol (5-AED) to that of ten other steroids: 17alpha-androstenediol… (More)
Is this relevant?
2003
2003
The purpose of this study was to investigate the efficacy of a novel steroid, fluasterone (DHEF, a dehydroepiandrosterone (DHEA… (More)
Is this relevant?
Review
2002
Review
2002
Prostate cancer is the most common male malignancy in western countries. Although primary prevention of prostate cancer is not… (More)
Is this relevant?
2002
2002
Experimental allergic encephalomyelitis (EAE), a Th1 polarized demyelinating disease of the central nervous system (CNS), shares… (More)
Is this relevant?
Review
2001
Review
2001
Progress in mechanism-based cancer prevention research may be facilitated by the use of animal models displaying specific genetic… (More)
Is this relevant?
1999
1999
Solubilization of nonpolar drugs constitutes one of the most important tasks in parenteral formulations design. This study… (More)
Is this relevant?
1999
1999
Solubility enhancement has broad implications in parenteral formulation design. A simple mathematical model has been developed to… (More)
Is this relevant?
Review
1996
Review
1996
Clinical chemoprevention trials of more than 30 agents and agent combinations are now in progress or being planned. The most… (More)
Is this relevant?
Review
1994
Review
1994
Chemoprevention drug development has the goal of identifying safe and effective chemopreventive agents for clinical use. Several… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?